SCHEMBL6209186

SCHEMBL6209186

Brc1cnc(Nc2ccc3cn[nH]c3c2)nc1NCc1ccccn1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTK2 Q05397 8/20 0.64
▸ PTK2B Q14289 6/20 0.64
▸ FGFR1 P11362 4/20 0.54
▸ IGF1R P08069 4/20 0.54
▸ KDR P35968 3/20 0.54
▸ EGFR P00533 3/20 0.52
▸ SYK P43405 3/20 0.48
▸ IDO1 P14902 1/20 0.47
▸ TDO2 P48775 1/20 0.47
▸ CDK1 P06493 3/20 0.47
▸ CDC7 O00311 1/20 0.45
▸ PLK4 O00444 1/20 0.43
▸ CHEK1 O14757 1/20 0.43
▸ MAPK13 O15264 1/20 0.43
▸ PDPK1 O15530 1/20 0.43
▸ DAPK3 O43293 1/20 0.43
▸ DYRK3 O43781 1/20 0.43
▸ JAK2 O60674 1/20 0.43
▸ ROCK2 O75116 1/20 0.43
▸ PRKD3 O94806 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6212988 0.92 PTK2 (0.75) PTK2PTK2BFGFR1IGF1RKDR
SCHEMBL6211871 0.90 PTK2 (0.53) PTK2PTK2BFGFR1IGF1RKDR
SCHEMBL6211361 0.88 PTK2 (0.64) PTK2PTK2BFGFR1IGF1RKDR
SCHEMBL6211607 0.86 PTK2 (0.64) PTK2PTK2BFGFR1IGF1RKDR
SCHEMBL6261250 0.85 PTK2 (0.86) PTK2PTK2BSYKCDK1CDC7
SCHEMBL6209807 0.83 PTK2 (0.66) PTK2PTK2BFGFR1IGF1RKDR
SCHEMBL6239489 0.82 KDR (0.57) PTK2PTK2BFGFR1IGF1RKDR
SCHEMBL6210226 0.82 PTK2 (0.61) PTK2PTK2BFGFR1IGF1RKDR
SCHEMBL6213157 0.82 PTK2 (0.61) PTK2PTK2BFGFR1IGF1RKDR
SCHEMBL15426063 0.81 INSR (0.54) PTK2PTK2BIGF1RIDO1TDO2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1578732-A2 PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH Pfizer Products Inc. (US) 2005-09-28 — — EP claimed
US-20040220177-A1 Compound for the treatment of abnormal cell growth PFIZER INC 2004-11-04 — — US claimed
WO-2004056786-A2 PYRIMIDINE DERIVATES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER PRODUCTS INC. (US) 2004-07-08 — — WO claimed
EP-1578732-A2 PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH Pfizer Products Inc. (US) 2005-09-28 — — EP disclosed
US-20040220177-A1 Compound for the treatment of abnormal cell growth PFIZER INC 2004-11-04 — — US disclosed
WO-2004056786-A2 PYRIMIDINE DERIVATES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER PRODUCTS INC. (US) 2004-07-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040220177-A1 Compound for the treatment of abnormal cell growth CCNA1, CCNB1, CCNT1 PTK2 3004/4885PTK2B 1941/4885FGFR1 21/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback